Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Published July 6, 2026 · Category: Finance

Overview

Can high-flying growth justify a premium valuation, or is a recovered value play the safer bet for 2026? Investors are weighing Eli Lilly and (NYSE:LLY) against Teva Pharmaceutical Industries (NYSE:TEVA) today.

Eli Lilly dominates the innovative brand-name drug market with blockbusters in metabolic health and oncology. Conversely, Teva focuses on generic medicines and biosimilars, looking to stabilize its business after years of legal and debt-related challenges. Both companies operate in the essential healthcare space but appeal to very different investor profiles.

Details

Eli Lilly discovers and manufactures medicines globally, focusing on areas like diabetes, obesity, and oncology. The company relies on major wholesale distributors such as McKesson Corp (NYSE:MCK), Cencora Inc. (NYSE:COR), and Cardinal Health (NYSE:CAH) for the majority of its U.S. distribution, meaning customer concentration adds a layer of risk. These partnerships are essential for getting products to patients within the pharmaceutical stocks category.

Continue reading

Source

Originally published at www.fool.com.

Related Articles

• Your 5 biggest questions about ‘Trump accounts,’ answered
• Nine microcap stocks of companies expected to grow sales by triple digits through 2028
• Low volatility stocks like insurers and REITs are suddenly turning into market leaders, Katie Stockton says